GP vs PF as Induction Chemotherapy Combined With CCRT for Locoregionally Advanced Nasopharyngeal Carcinoma

Overview

The purpose of this study is to compare the survival and toxicity of GP (gemcitabine and cisplatin) vs. PF (cisplatin and fluorouracil) as induction chemotherapy combined with concurrent chemoradiotherapy (CCRT) for locoregionally advanced nasopharyngeal carcinoma( NPC ) patients.

Full Title of Study: “GP vs PF as Induction Chemotherapy Combined With CCRT for Locoregionally Advanced Nasopharyngeal Carcinoma:a Prospective,Parallel, Randomized, Open Labeled, Multicenter Phase III Clinical Trial”

Study Type

  • Study Type: Interventional
  • Study Design
    • Allocation: Randomized
    • Intervention Model: Parallel Assignment
    • Primary Purpose: Treatment
    • Masking: None (Open Label)
  • Study Primary Completion Date: August 31, 2026

Detailed Description

Patients presented with non-keratinizing NPC and stage T1-4N2-3/T4N0-1M0 are randomly assigned to receive GP (gemcitabine and cisplatin) or PF (cisplatin and fluorouracil) induction chemotherapy combined with concurrent chemoradiotherapy. Patients in both arms receive radical radiotherapy, and cisplatin (100mg/m²) every three weeks for two cycles during radiotherapy. Patients in the investigational arm receive gemcitabine (1000 mg/m² d1,8) and cisplatin (80mg/m² d1) every 3 weeks for three cycles. Patients in the control arm receive fluorouracil (800mg/m² d1-5) and cisplatin (80mg/m² d1) every 3 weeks for three cycles. Our primary endpoint is progress-free survival (PFS). Secondary end points include distant metastasis-free survival (DMFS), overall survival (OS), locoregional relapse-free survival (LRRFS), initial response rates after treatments, toxic effects and quality of life (QoL).

Interventions

  • Drug: gemcitabine and cisplatin
    • Patients receive gemcitabine (1000 mg/m² d1,8) and cisplatin (80mg/m² d1) every 3 weeks for 3 cycles before concurrent chemoradiotherapy.
  • Drug: cisplatin and fluorouracil
    • Patients receive fluorouracil (800mg/m2 d1-5) and cisplatin (80mg/m² d1) every 3 weeks for 3 cycles before concurrent chemoradiotherapy.
  • Radiation: IMRT
    • Intensity modulated-radiotherapy (IMRT) is given as 30~33 fraction with five daily fractions per week for 6-7 weeks to a total dose of 68~70 Gy to the primary tumor
  • Drug: cisplatin
    • IMRT concurrently with cisplatin 100 mg/m² every 3 weeks for 2 cycles.

Arms, Groups and Cohorts

  • Experimental: gemcitabine and cisplatin
    • Patients receive gemcitabine (1000 mg/m² d1,8) and cisplatin (80mg/m² d1) every 3 weeks for 3 cycles before radiotherapy, and then receive intensity modulated-radiotherapy (IMRT), concurrently with cisplatin 100 mg/m² every 3 weeks for 2 cycles.
  • Active Comparator: cisplatin and fluorouracil
    • Patients receive fluorouracil (800mg/m² d1-5) and cisplatin (80mg/m² d1) every 3 weeks for 3 cycles before radiotherapy, and then receive intensity modulated-radiotherapy (IMRT), concurrently with cisplatin 100 mg/m² every 3 weeks for 2 cycles.

Clinical Trial Outcome Measures

Primary Measures

  • progress-free survival (PFS)
    • Time Frame: 3 years
    • Progress-free survival is calculated from the date of randomization to the date of the first progress at any site.

Secondary Measures

  • Distant Metastasis-Free Survival (DMFS)
    • Time Frame: 3 years
    • The DMFS is evaluated and calculated from the date of random assignment until the day of first distant metastases or until the date of the last follow-up visit.
  • Overall Survival (OS)
    • Time Frame: 3 years
    • The OS was defined as the duration from the date of random assignment to the date of death from any cause or censored at the date of the last follow-up.
  • Locoregional Relapse-Free Survival (LRRFS)
    • Time Frame: 3 years
    • The LRRFS is evaluated and calculated from the date of random assignment until the day of first locoregional relapse or until the date of the last follow-up visit.
  • Number of participants with adverse events
    • Time Frame: up to 3 years
    • Incidence of acute and late toxicity

Participating in This Clinical Trial

Inclusion Criteria

  • Patients with newly histologically confirmed non-keratinizing nasopharyngeal carcinoma, including WHO II or III – Tumor staged as T1-4N2-3/T4N0-1M0(according to the 8th AJCC edition) – Male and no pregnant female – Age between 18-65 – Adequate marrow: leucocyte count ≥4000/μL, hemoglobin ≥90g/L and platelet count ≥100000/μL – Normal liver function test: Alanine Aminotransferase (ALT)、Aspartate Aminotransferase (AST) <2.0×upper limit of normal (ULN) – Adequate renal function: creatinine clearance ≥60 ml/min – Satisfactory performance status: Karnofsky scale (KPS) ≥ 70 – Without radiotherapy or chemotherapy – Patients must give signed informed consent Exclusion Criteria:

  • Evidence of relapse or distant metastasis – History of prior malignancy or previous treatment for NPC – Any severe intercurrent disease, which may bring unacceptable risk or affect the compliance of the trial, for example, unstable cardiac disease requiring treatment, renal disease, chronic hepatitis, diabetes with poor control (fasting plasma glucose >1.5×ULN), and emotional disturbance. – Pregnancy or lactation

Gender Eligibility: All

Minimum Age: 18 Years

Maximum Age: 65 Years

Are Healthy Volunteers Accepted: No

Investigator Details

  • Lead Sponsor
    • Sun Yat-sen University
  • Collaborator
    • Affiliated Cancer Hospital & Institute of Guangzhou Medical University
  • Provider of Information About this Clinical Study
    • Principal Investigator: Ming-Yuan Chen, Principal Investigator – Sun Yat-sen University
  • Overall Official(s)
    • Ming-Yuan Chen, MD,PhD, Principal Investigator, Sun Yat-sen University

Clinical trials entries are delivered from the US National Institutes of Health and are not reviewed separately by this site. Please see the identifier information above for retrieving further details from the government database.

At TrialBulletin.com, we keep tabs on over 200,000 clinical trials in the US and abroad, using medical data supplied directly by the US National Institutes of Health. Please see the About and Contact page for details.